Active Stocks
Mon Mar 04 2024 11:10:47
  1. Tata Steel share price
  2. 153.35 -1.16%
  1. Bharti Airtel share price
  2. 1,145.70 1.34%
  1. Larsen & Toubro share price
  2. 3,631.85 -0.61%
  1. NTPC share price
  2. 356.85 4.39%
  1. Power Grid Corporation Of India share price
  2. 293.25 2.21%
Business News/ Science / Health/  Serum Institute denies side effects claim, says Covishield 'safe and immunogenic

Serum Institute denies side effects claim, says Covishield 'safe and immunogenic

Serum Institute of India claims, 'Covishield is safe and immunogenic'
  • Serum Institute said the incident with the Chennai vvolunteer is no way induced by it
  • Serum Institute plans to produce up to 1 billion doses of the Covishield vaccinePremium
    Serum Institute plans to produce up to 1 billion doses of the Covishield vaccine

    After a Chennai-based man claimed that he suffered neurological and psychological side effects taking a shot of Covid-19 vaccine Covishield during the human trial being conducted by Serum Institute of India's (SII), the Pune-based company said there was no correlation between the two. In a social media post, the institute said, "Covishield is safe & immunogenic, the incident with the Chennai volunteer no way induced by the vaccine."

    Addressing concerns related to the serious adverse event reported by a volunteer in Chennai, SII said, "Serum Institute of India is sympathetic with the volunteer's medical condition. However, we would like to clarify that all the requisite regulatory and ethical processes and guidelines were followed diligently and strictly. The concerned authorities were informed and the Principal Investigator, DSMB and the Ethics Committee independently cleared and reckoned it as a non-related issue to the vaccine trial. Post which we submitted all the reports and data related to the incident to the DCGI. It is only after we cleared all the required processes that we continued with the trials."

    SII further stated that the vaccine won’t be released for mass use unless it is proven immunogenic, and safe. "The legal notice was sent to safeguard the reputation of the company which is being unfairly maligned: Serum Institute of India," said SII.

    SII is conducting clinical trials of AstraZeneca-Oxford's Covid-19 vaccine candidate in India. Currently, the phase-3 clinical trial of Covaxin is being conducted across India involving 26,000 participants. The vaccine will be produced in the Biosafety Level 3 production facility of the company.

    The vaccine candidate, Covishield, is being developed by the UK's Oxford University and US pharma giant AstraZeneca. The SII is a manufacturing partner for the vaccine.

    Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

    Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Check all the latest action on Budget 2024 here. Download The Mint News App to get Daily Market Updates.
    More Less
    Published: 01 Dec 2020, 01:00 PM IST
    Next Story footLogo
    Recommended For You
    Switch to the Mint app for fast and personalized news - Get App